Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
- CHF | -.--% | -.--% | -.--% |
06-20 | Sector Update: Health Care Stocks Lean Lower Pre-Bell Thursday | MT |
06-18 | Cara Therapeutics to Idle 70% Workforce, Explore Alternatives After Scrapping Notalgia Paresthetica Program | MT |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Strengths
- Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-.--% | 14.38M | - | ||
-0.13% | 39.05B | A- | ||
-10.43% | 33.74B | B- | ||
+78.96% | 28.54B | A | ||
-14.82% | 15.59B | C | ||
-3.06% | 13.69B | B- | ||
-12.76% | 11.44B | D+ | ||
+181.73% | 10.66B | D | ||
-53.92% | 9.27B | B | ||
+5.69% | 9.13B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- CARA Stock
- 69C Stock
- Ratings Cara Therapeutics, Inc.